By Application
Hot products 
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
-
Mouse Anti-ATG5 Recombinant Antibody (9H197) (CBMAB-A3945-YC)
-
Mouse Anti-DLL4 Recombinant Antibody (D1090) (CBMAB-D1090-YC)
-
Mouse Anti-APOH Recombinant Antibody (4D9A4) (CBMAB-A3249-YC)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-dsDNA Recombinant Antibody (22) (CBMAB-AP1954LY)
-
Mouse Anti-ADAM12 Recombinant Antibody (V2-179752) (CBMAB-A1114-YC)
-
Mouse Anti-AMOT Recombinant Antibody (CBYC-A564) (CBMAB-A2552-YC)
-
Mouse Anti-ELAVL4 Recombinant Antibody (6B9) (CBMAB-1132-YC)
-
Mouse Anti-APP Recombinant Antibody (DE2B4) (CBMAB-1122-CN)
-
Rat Anti-ADAM10 Recombinant Antibody (V2-179741) (CBMAB-A1103-YC)
-
Rabbit Anti-ALDOA Recombinant Antibody (D73H4) (CBMAB-A2314-YC)
-
Mouse Anti-ADGRE2 Recombinant Antibody (V2-261270) (CBMAB-C0813-LY)
-
Rabbit Anti-CBL Recombinant Antibody (D4E10) (CBMAB-CP0149-LY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0442) (CBMAB-0445-YY)
-
Mouse Anti-AMH Recombinant Antibody (5/6) (CBMAB-A2527-YC)
-
Mouse Anti-CD83 Recombinant Antibody (HB15) (CBMAB-C1765-CQ)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Mouse Anti-CCS Recombinant Antibody (CBFYC-1093) (CBMAB-C1150-FY)
-
Mouse Anti-BRCA2 Recombinant Antibody (CBYY-0790) (CBMAB-0793-YY)
Skin Cancer (SCC)
Fig.1 Squamous cell skin cancer
Squamous-cell skin cancer, also named as cutaneous squamous-cell carcinoma (cSCC), is one of the typical types of skin cancer along with melanoma and basal cell cancer. Normally, it presents as a hard lump with a scaly top but can also deteriorate into an ulcer. Onset is often several months. Squamous-cell skin cancer is more likely to spread to distant areas comparing with basal cell cancer. The greatest risk factor is the high total exposure to ultraviolet radiation from the sun. Squamous cell cancers happening in the ears and lip have high possibilities of local recurrence and distant metastasis (about 20–50%). SCCs represent around 20% of the non-melanoma skin cancers, but on account of their more obvious nature and growth rates, they stands for 90% of all head and neck cancers that are primarily presented. CD10, as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma, has been studied.
Loading...
Compare
